AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36444513 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ VAS (per 10 unit increase)
Number of subjects: 30432
Study 36444513 — intervention group
Group type: EXPERIMENTAL
Intervention: DSST (per 5 unit increase)
Number of subjects: 30432
Study 36444764 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Cohosh (BC) extract, treated for an average of 24.5 days (median 25; range 15-36)
Number of subjects: 31
Study 36444764 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study 36444834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried patients receiving reperfusion treatment
Number of subjects: 19912
Study 36444834 — intervention group
Group type: COMPARATOR
Intervention: In-hospital death
Number of subjects: 19912
Study 36444834 — intervention group
Group type: COMPARATOR
Intervention: 2-year all-cause death
Number of subjects: 19912
Study 36444834 — intervention group
Group type: COMPARATOR
Intervention: 2-year major adverse cardiac and cerebrovascular events (a composite of all-cause death, myocardial infarction, or stroke)
Number of subjects: 19912
Study 36444858 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal disease (PPG >0.73)
Number of subjects: 113
Study 36444858 — intervention group
Group type: COMPARATOR
Intervention: Diffuse disease (PPG ≤0.73)
Number of subjects: 113
Study 36444863 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 1498
Study 36444863 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 1498
Study 36444865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ECGs measuring intra-QRS peaks (QRSp)
Number of subjects: 143
Study 36444865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter-defibrillators
Number of subjects: 143
Study 36445158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention (TTVI)
Number of subjects: 2628
Study 36445230 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpancreaticoduodenectomy (PD) with routine monitoring in ICU/IMC
Number of subjects: 192
Study 36445230 — intervention group
Group type: EXPERIMENTAL
Intervention: PANCRHEMO Score 1
Number of subjects: 192
Study 36445230 — intervention group
Group type: EXPERIMENTAL
Intervention: PANCRHEMO Score 2
Number of subjects: 192
Study 36445250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal tube (iLTS-D)
Number of subjects: 0
Study 36445250 — intervention group
Group type: COMPARATOR
Intervention: Ambu® Auragain™
Number of subjects: 0
Study 36445410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral V937 + intravenous pembrolizumab 2 mg/kg Q3W
Number of subjects: 36
Study 36445467 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA (ProRoot WMTA)
Number of subjects: 108
Study 36445467 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 108
Study 36445467 — intervention group
Group type: EXPERIMENTAL
Intervention: TotalFill
Number of subjects: 108
Study 36445467 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal wall thickness
Number of subjects: 108
Study 36445668 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (HFrEF, HFmrEF, HFpEF)
Number of subjects: 400
Study 36445668 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary arterial hypertension (PAH) patients
Number of subjects: 400
Study 36445676 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT scan for diagnosis of generator pocket infection
Number of subjects: 21
Study 36445676 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT scan for diagnosis of lead-dependent intracardiac infection
Number of subjects: 21
Study 36445676 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT scan reclassification of diagnosis
Number of subjects: 21
Study 36445676 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-infectious indications)
Number of subjects: 21
Study 36445734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhera CARINAE Digital Health Program
Number of subjects: 60
Study 36445734 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 60
Study 36445882 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) and iron supplements as per guidelines
Number of subjects: 1980
Study 36445882 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 1980
Study 36445944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (oral PPAR-α agonist)
Number of subjects: 30
Study 36446040 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-event continuous reassessment method (TiTE-CRM)
Number of subjects: 0
Study 36446040 — intervention group
Group type: EXPERIMENTAL
Intervention: TiTE-CRM methodology
Number of subjects: 0
Study 36446450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 diagnosis at discharge
Number of subjects: 6054
Study 36446450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiac causes of death
Number of subjects: 6054
Study 36446450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with non-cardiovascular causes of death
Number of subjects: 6054
Study 36446450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vascular causes of death
Number of subjects: 6054
Study 36446450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 related causes of death
Number of subjects: 6054
Study 36446452 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 250
Study 36446452 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant chemotherapy
Number of subjects: 250
Study 36446452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant therapy, surgery and adjuvant chemotherapy
Number of subjects: 250
Study 36446452 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment complications
Number of subjects: 250
Study 36446452 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' anxiety and depression
Number of subjects: 250
Study 36446453 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk factors for acute and chronic postoperative pain
Number of subjects: 10000
Study 36446453 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical risk factors
Number of subjects: 10000
Study 36446453 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain outcomes
Number of subjects: 10000
Study 36446453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for postoperative pain
Number of subjects: 10000
Study 36446465 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 7
Study 36446465 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 7
Study 36446481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET) in children with asthma
Number of subjects: 446
Study 36446481 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (CPET) in healthy children
Number of subjects: 446
Study 36446676 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary telehealth-enhanced home visits combined with peer mentoring (4 structured home visits + 16 weeks of peer mentoring)
Number of subjects: 51
Study 36446676 — intervention group
Group type: COMPARATOR
Intervention: Usual care (historical controls)
Number of subjects: 51
Study 36446676 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 51
Study 36446676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (IN-HOME-PD)
Number of subjects: 51
Study 36447027 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults with OSA
Number of subjects: 371
Study 36447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 132
Study 36447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Being insured
Number of subjects: 132
Study 36447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer fatalism
Number of subjects: 132
Study 36447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 132
Study 36447190 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced present orientation
Number of subjects: 132
Study 36447190 — intervention group
Group type: COMPARATOR
Intervention: Nativity (Sub-Saharan African immigrants vs African Americans)
Number of subjects: 132
Study 36447337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 31
Study 36447613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Lamivudine
Number of subjects: 0
Study 36447613 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36447615 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 4664
Study 36448227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelarabine continuous infusion (CI) for 5 days (120 hours) at escalating doses from 100 to 800 mg/m2
Number of subjects: 29
Study 36448274 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% human intravenous immunoglobulin (IVIg) BT595, total dose of 2 g/kg body weight over 2 or 5 days
Number of subjects: 34
Study 36448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterocheck WB
Number of subjects: 531
Study 36448816 — intervention group
Group type: EXPERIMENTAL
Intervention: CTK IgG
Number of subjects: 531
Study 36448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterocheck
Number of subjects: 531
Study 36448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine commercially available Salmonella Typhi RDTs
Number of subjects: 531
Study 36449027 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation (surgical management)
Number of subjects: 91
Study 36449027 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 91
Study 36449262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenadogene nolparvovec gene therapy
Number of subjects: 174
Study 36449262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection of lenadogene nolparvovec
Number of subjects: 174
Study 36449262 — intervention group
Group type: COMPARATOR
Intervention: Natural history
Number of subjects: 174
Study 36449285 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light phototherapy
Number of subjects: 0
Study 36449335 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO app (electronic Patient-Reported Outcome)
Number of subjects: 0
Study 36449341 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (standardized delivery format)
Number of subjects: 205
Study 36449341 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (self-tailored delivery format)
Number of subjects: 205
Study 36449341 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 205
Study 36449446 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36449695 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP)
Number of subjects: 202
Study 36449695 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 202
Study 36449695 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SUVmax at cycle 2 (C2)
Number of subjects: 202
Study 36449695 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TILs and DTILs
Number of subjects: 202
Study 36450120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pelvic Pain
Number of subjects: 0
Study 36450120 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic Controls
Number of subjects: 0
Study 36450289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression (CBT-AD) delivered by a nurse, conducted once weekly for 12 sessions.
Number of subjects: 5
Study 36450379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg intravenously every 3 weeks)
Number of subjects: 0
Study 36450384 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 240
Study 36450384 — intervention group
Group type: EXPERIMENTAL
Intervention: History of immune-related adverse events (irAEs)
Number of subjects: 240
Study 36450385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 1 mg/kg and Ipilimumab (IPI) 3 mg/kg
Number of subjects: 56
Study 36450385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 3 mg/kg and Ipilimumab (IPI) 1 mg/kg
Number of subjects: 56
Study 36450385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) induction therapy
Number of subjects: 56
Study 36450385 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker analyses
Number of subjects: 56
Study 36450386 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) followed by nivolumab (240 mg every 2 weeks for up to 24 doses)
Number of subjects: 42
Study 36450386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 42
Study 36450427 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (intervention group)
Number of subjects: 1353
Study 36450427 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1353
Study 36450746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccine
Number of subjects: 764
Study 36450763 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 366
Study 36450763 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab (TH)
Number of subjects: 366
Study 36450938 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) at a dose of 5 mg/kg 24 hours prior to surgery
Number of subjects: 51
Study 36450938 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRF imaging
Number of subjects: 51
Study 36450944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) measuring neck fluid volume (NFV) and leg fluid volume (LFV) at preoperative, PACU, N 0, and POD 1 time points
Number of subjects: 35
Study 36450944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 35
Study 36450944 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility measures of recruitment and protocol adherence
Number of subjects: 35
Study 36451004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glittre ADL Test
Number of subjects: 25
Study 36451029 — intervention group
Group type: COMPARATOR
Intervention: Intravenous spesolimab (0.01-0.3 mg/kg and ≥ 0.3 mg/kg)
Number of subjects: 0
Study 36451029 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous spesolimab (150-600 mg)
Number of subjects: 0
Study 36451029 — intervention group
Group type: COMPARATOR
Intervention: Intravenous spesolimab
Number of subjects: 0
Study 36451029 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous spesolimab
Number of subjects: 0
Study 36451029 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study 36451062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tween-20 detergent lysis (DLT) method with 2-h incubation at 37 °C
Number of subjects: 0
Study 36451062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tween-20 detergent lysis (DLT) method with 4-h incubation at room temperature
Number of subjects: 0
Study 36451062 — intervention group
Group type: COMPARATOR
Intervention: Repeated freeze-thaw (RFT) method
Number of subjects: 0
Study 36451114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive inpatient treatment program (APT + VITA)
Number of subjects: 280
Study 36451114 — intervention group
Group type: EXPERIMENTAL
Intervention: APT
Number of subjects: 280
Study 36451114 — intervention group
Group type: EXPERIMENTAL
Intervention: VITA
Number of subjects: 280
Study 36451114 — intervention group
Group type: COMPARATOR
Intervention: Wait list (TAU)
Number of subjects: 280
Study 36451162 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasonography (CUS) of proximal lower limb veins within 48 hours from admission and at discharge
Number of subjects: 2100
Study 36451162 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Dimer measurement and IMPROVE-DD score assessment
Number of subjects: 2100
Study 36451162 — intervention group
Group type: EXPERIMENTAL
Intervention: CUS at admission
Number of subjects: 2100
Study 36451162 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 2100
Study 36451175 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized PWUD-HCV care model using pangenotypic direct acting antivirals (DAAs) for HCV treatment.
Number of subjects: 0
Study 36451175 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with addiction care professionals and board members.
Number of subjects: 0
Study 36451198 — intervention group
Group type: COMPARATOR
Intervention: 4D flow CMR parameters in PAH patients
Number of subjects: 45
Study 36451198 — intervention group
Group type: EXPERIMENTAL
Intervention: RV direct flow
Number of subjects: 45
Study 36451226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation services received, assessed using the S-KAS scale after 12 months of follow-up.
Number of subjects: 250
Study 36451226 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported practices in smoking cessation by clinicians, assessed using the S-KAP scale.
Number of subjects: 250
Study 36451242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV)
Number of subjects: 138
Study 36451242 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan 60 mg/amlodipine 10 mg (FMS/ALD)
Number of subjects: 138
Study 36451242 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan 60 mg + rosuvastatin 20 mg (FMS + RSV)
Number of subjects: 138
Study 36451252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injections (0.5 mg/0.05 mL)
Number of subjects: 80
Study 36451252 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal conbercept (IVC) injections (0.5 mg/0.05 mL)
Number of subjects: 80
Study 36451252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IVR and IVC
Number of subjects: 80
Study 36451311 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 3142
Study 36451312 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicle long RNA (evlRNA) sequencing
Number of subjects: 0
Study 36451312 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM model based on a 23-gene signature
Number of subjects: 0
Study 36451312 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM model based on a 17-gene signature
Number of subjects: 0
Study 36451312 — intervention group
Group type: EXPERIMENTAL
Intervention: EvlRNAs in serum
Number of subjects: 0
Study 36451848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13.
Number of subjects: 0
Study 36452171 — intervention group
Group type: EXPERIMENTAL
Intervention: BL10 gel
Number of subjects: 18
Study 36452171 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA gel
Number of subjects: 18
Study 36452171 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 18
Study 36452315 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative information in a decision aid
Number of subjects: 0
Study 36452315 — intervention group
Group type: COMPARATOR
Intervention: Qualitative information in a decision aid
Number of subjects: 0
Study 36452492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate and TRIS
Number of subjects: 0
Study 36452492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 0
Study 36452901 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT103-T autologous T cell therapy
Number of subjects: 0
Study 36452901 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide conditioning
Number of subjects: 0
Study 36452951 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth consultations proposed and accepted in almost 40% of cases.
Number of subjects: 0
Study 36452951 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-drainage as a replacement for physiotherapy sessions.
Number of subjects: 0
Study 36452951 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications usage.
Number of subjects: 0
Study 36452951 — intervention group
Group type: EXPERIMENTAL
Intervention: Social class impact on behavior and healthcare access.
Number of subjects: 0
Study 36452951 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual follow-up clinic visits.
Number of subjects: 0
Study 36452951 — intervention group
Group type: EXPERIMENTAL
Intervention: Required hospitalizations for exacerbation.
Number of subjects: 0
Study 36453122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (pain group)
Number of subjects: 20
Study 36453122 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection (control group)
Number of subjects: 20
Study 36453450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol
Number of subjects: 0
Study 36453455 — intervention group
Group type: EXPERIMENTAL
Intervention: Most elliptical annulus tertile
Number of subjects: 1732
Study 36453455 — intervention group
Group type: COMPARATOR
Intervention: Circular annulus
Number of subjects: 1732
Study 36453629 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps per day physical activity intervention for 6 months
Number of subjects: 24
Study 36453629 — intervention group
Group type: COMPARATOR
Intervention: Control group of age-matched patients with Marfan syndrome
Number of subjects: 24
Study 36453638 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation (UCBT) using either 5/6 or 6/6 UCB as the cell source, with fully ablative busulfan, cyclophosphamide, and fludarabine without serotherapy.
Number of subjects: 55
Study 36453638 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation (UCBT)
Number of subjects: 55
Study 36453656 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) ≥140 mmHg at age 40-43 years
Number of subjects: 2424